Can J Gastroenterol Hepatol. 2014 Jun;28(6):330-4. doi: 10.1155/2014/751921.
There are data suggesting a link between proton pump inhibitor (PPI) use and the development of spontaneous bacterial peritonitis (SBP) in cirrhotic patients with ascites; however, these data are controversial.
To assess whether the use of PPIs in cirrhotic patients with ascites is associated with an increased risk for SBP.
A retrospective case-control study (June 2004 to June 2010) was conducted at the Centre Hospitalier de l'Université de Montréal in Montreal, Quebec. Fifty-one cirrhotic patients admitted with paracentesis-proven SBP (≥250 neutrophils/mm3), occurring within seven days of hospital admission, met the inclusion criteria. These patients were matched 1:2 (for age, Child-Pugh class and year of admission) with 102 comparable cirrhotic patients with ascites who were admitted for conditions other than SBP.
Patients with SBP had a significantly higher rate of pre-hospital PPI use (60.8%) compared with cirrhotic patients without SBP (42.2%; P=0.03). On multivariate analysis, PPI use was the only factor independently associated with SBP (OR 2.09 [95% CI 1.04 to 4.23]; P=0.04). Thirty-five (35%) patients in both groups had no documented indication for PPI use in their charts. Forty-five percent of the remaining cirrhotic patients with SBP had an inappropriate indication, as defined in the protocol, for PPI use compared with 25% of controls.
Cirrhotic patients with SBP were twice as likely to have taken PPIs than patients without SBP. These findings reinforce the association between PPI use and SBP observed in other studies. A high percentage of cirrhotic patients were taking a PPI without any documented indication.
有数据表明质子泵抑制剂(PPI)的使用与肝硬化腹水患者自发性细菌性腹膜炎(SBP)的发展之间存在关联;然而,这些数据存在争议。
评估肝硬化腹水患者使用 PPI 是否会增加 SBP 的风险。
这是一项在魁北克省蒙特利尔大学医疗中心进行的回顾性病例对照研究(2004 年 6 月至 2010 年 6 月)。符合纳入标准的 51 例肝硬化患者因腹水行诊断性腹腔穿刺术,发现腹水白细胞计数≥250 个/毫米 3 且发生在入院后 7 天内,证实患有 SBP。这些患者按照年龄、Child-Pugh 分级和入院年份与 102 例因 SBP 以外疾病入院的肝硬化腹水对照患者进行 1:2 匹配。
患有 SBP 的患者在入院前使用 PPI 的比例(60.8%)明显高于未发生 SBP 的肝硬化患者(42.2%;P=0.03)。多变量分析显示,PPI 使用是唯一与 SBP 独立相关的因素(OR 2.09 [95%CI 1.04 至 4.23];P=0.04)。两组中均有 35(35%)例患者的病历中没有记录使用 PPI 的明确指征。与对照组(25%)相比,SBP 组中 45%的剩余肝硬化患者使用 PPI 的指征不恰当,而该指征是在方案中定义的。
患有 SBP 的肝硬化患者使用 PPI 的可能性是未发生 SBP 的患者的两倍。这些发现强化了其他研究中观察到的 PPI 使用与 SBP 之间的关联。很大一部分肝硬化患者在没有任何记录的情况下使用 PPI。